Results 1 to 10 of about 2,540 (169)

Cost-effectiveness of inclisiran in patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective. [PDF]

PLoS ONE
BackgroundAtherosclerotic cardiovascular disease (ASCVD) imposes a substantial clinical and economic burden in China. Despite maximally tolerated statin therapy, many patients fail to achieve recommended low-density lipoprotein cholesterol (LDL-C ...
Mochou Liu, Xinyue Zhang, Mengwen Feng, Qingfeng He, Zhen Feng   +4 more
doaj   +2 more sources

Low‐Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION‐INCEPTION, a Randomized, Controlled, Open‐Label Trial [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The low‐density lipoprotein cholesterol (LDL‐C)‐lowering effect of inclisiran, a proprotein convertase subtilisin/kexin type 9‐targeting small interfering RNA, has not been established in patients with recent acute coronary syndrome.
Kirk U. Knowlton, Ann Marie Navar, Jeffrey L. Anderson, Alan S. Brown, Joseph B. Muhlestein, Kelly Kleeman, Samiha Sarwat, Cheryl A. Abbas, Mary Ann Ramirez, Cindy L. Grines, Wael S. Abo‐Auda, Nihar R. Desai   +11 more
doaj   +2 more sources

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States [PDF]

JACC: Advances
Background: Many patients do not reach recommended low-density lipoprotein cholesterol (LDL-C) levels on statins alone. Inclisiran is a small interfering RNA providing ∼50% further reduction in LDL-C.
Nathan D. Wong, PhD, MPH, Hridhay Karthikeyan, MS, BS, Wenjun Fan, MD, PhD, MS, Batul Electricwala, PhD   +3 more
doaj   +2 more sources

Inclisiran for the treatment of hypercholesterolaemia

Drugs in Context
Inclisiran is a synthetic small interfering RNA (siRNA) that inhibits the production of proprotein convertase subtilisin/ kexin 9 (PCSK9) in hepatocytes by silencing the translation of PCSK9 mRNA.
Joel C Marrs, Sarah L Anderson
doaj   +3 more sources

Inclisiran: A New Pharmacological Approach for Hypercholesterolemia

Reviews in Cardiovascular Medicine, 2022
Therapeutic approaches based on gene silencing technologies represent a new opportunity to manage hypercholesterolemia. Inclisiran is a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA.
Stefania Angela Di Fusco, Aldo Pietro Maggioni, Chiara Bernelli, Francesco Perone, Vincenzo De Marzo, Edoardo Conte, Francesca Musella, Giuseppe Uccello, Leonardo De Luca, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva, Furio Colivicchi   +12 more
doaj   +3 more sources

Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management [PDF]

BMC Cardiovascular Disorders
Background Inclisiran is a novel small interfering RNA therapeutic developed to lower lipid levels by targeting hepatic production of proprotein convertase subtilisin/kexin type 9.
Shakta Mani Satyam, Mohamed El-Tanani, Mohamed Anas Patni, Abdul Rehman, Sara Muhammad Irshad, Reem Raheem, Esha Junais, Ashika Anu John, Rena Yusuf Rassal, Rashmi Kumari, Sainath P   +10 more
doaj   +2 more sources

Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective. [PDF]

Clin Transl Sci
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Yuan Y, Sharma V, Bhattaram VA, Pan X, Earp J, Wang Y, Liu J, Zhu H.   +7 more
europepmc   +2 more sources

Real-World Adherence and Effectiveness of Inclisiran in Lowering LDL-C: Results from 1 Year of Follow-Up [PDF]

Cardiology and Therapy
Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment.
Christie M. Ballantyne, Timothy E. Graham, Lucinda J. Van Anglen, Bruce J. Iteld, Harvey Serota, Xiaoli Niu, Sean McElligott, Kelly E. Hanna, Tyler J. Varisco   +8 more
doaj   +2 more sources

Inclisiran in Dyslipidemia with High Residual Platelet Reactivity [PDF]

Diseases
Background: High residual platelet reactivity (HRPR) and persistent dyslipidemia remain important unmet needs in cardiovascular risk management, particularly in patients undergoing coronary revascularization.
Dina Kapsultanova, Sholpan Zhangelova, Friba Nurmukhammad, Zulfiya Makasheva, Orazbek Sakhov, Tamara Galkina, Farida Rustamova, Dana Akhmentayeva, Botakoz Aubakirova   +8 more
doaj   +2 more sources

Inclisiran for fast-track lipid-lowering treatment early after an acute coronary syndrome: a pilot study [PDF]

Atherosclerosis Plus
Background: Elevated low-density lipoprotein cholesterol (LDL-C) after acute coronary syndrome (ACS) significantly increases cardiovascular risk. Timely reduction of LDL-C is crucial, but it takes several weeks to achieve optimal LDL-C levels with ...
Alessandro Lupi, Martino Baluci, Simone Persampieri, Iacopo Perversi, Davide Presutti, Alberto Somaschini, Giovanni Vincenzo Gaudio, Luigina Guasti, Marc Ferrini, Alberto Corsini, Roberto De Ponti   +10 more
doaj   +2 more sources